Company research
Cardiff Oncology, Inc.
CIK 1213037Updated Nov 13, 2026
SecurityCRDF · NASDAQ · equity
Historical securities (1)
TROVW · NASDAQ · warrant · closed Jan 15, 2025Name history
Trovagene, Inc. · through May 7, 2020TrovaGene Inc. · through Mar 4, 2013XENOMICS INC · through Jun 3, 2009USED KAR PARTS INC · through Jun 30, 2004
CRDF price & chart
Loading TradingView…
NASDAQ:CRDF on TradingView ↗About the company
Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
In the news
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference ↗
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge News provided by USA News Group Mar 08, 2025, 07:33 ET Share this article Share to X Share this article Share to X USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Mar ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 5.02, 5.03, 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 63,780,000Source | 62,896,000Source | 37,329,000Source | 75,739,000Source | 66,051,000Source | 49,172,000Source | 84,807,000Source | 74,038,000Source | 61,884,000Source | 97,190,000Source | 81,637,000Source | 116,191,000Source |
| Property, Plant and Equipment, NetUSD | 666,000Source | 993,000Source | 450,000Source | 743,000Source | 1,095,000Source | 491,000Source | 805,000Source | 1,199,000Source | 578,000Source | 898,000Source | 1,238,000Source | 1,269,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,135,000Source | 13,038,000Source | 9,197,000Source | 10,784,000Source | 25,501,000Source | 8,544,000Source | 24,095,000Source | 18,658,000Source | 17,470,000Source | 51,470,000Source | 21,655,000Source | 16,347,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 254,000Source | 618,000Source | 189,000Source | 526,000Source | 451,000Source | 191,000Source | 405,000Source | 393,000Source | 182,000Source | 773,000Source | 288,000Source | 771,000Source |
| Assets, CurrentUSD | 61,801,000Source | 59,332,000Source | 35,592,000Source | 73,696,000Source | 62,246,000Source | 47,342,000Source | 82,711,000Source | 69,990,000Source | 60,128,000Source | 95,054,000Source | 77,412,000Source | 111,284,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 2,301,000Source | 5,246,000Source |
| Operating Lease, Right-of-Use AssetUSD | 764,000Source | 1,304,000Source | 360,000Source | 899,000Source | 1,439,000Source | 495,000Source | 1,034,000Source | 1,574,000Source | 629,000Source | 1,169,000Source | 1,708,000Source | 2,251,000Source |
| Other Assets, NoncurrentUSD | 549,000Source | 1,267,000Source | 927,000Source | 401,000Source | 1,271,000Source | 844,000Source | 257,000Source | 1,275,000Source | 549,000Source | 69,000Source | 1,279,000Source | 1,387,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 14,990,000Source | 13,504,000Source | 10,797,000Source | 17,133,000Source | 13,663,000Source | 14,463,000Source | 13,931,000Source | 13,144,000Source | 16,496,000Source | 14,241,000Source | 11,898,000Source | 9,848,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 7,000Source | 5,000Source | 7,000Source | 7,000Source | 5,000Source | 7,000Source | 7,000Source | 4,000Source | 7,000Source | 7,000Source | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 471,547,000Source | 421,697,000Source | 478,194,000Source | 470,138,000Source | 413,017,000Source | 477,126,000Source | 468,455,000Source | 409,781,000Source | 475,361,000Source | 467,087,000Source | 409,343,000Source | 404,834,000Source |
| Retained Earnings (Accumulated Deficit)USD | -422,814,000Source | -372,392,000Source | -451,607,000Source | -411,556,000Source | -360,537,000Source | -442,375,000Source | -397,613,000Source | -348,759,000Source | -430,030,000Source | -384,179,000Source | -339,541,000Source | -298,100,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 50,000Source | 82,000Source | -62,000Source | 17,000Source | -97,000Source | -49,000Source | 27,000Source | -132,000Source | 50,000Source | 34,000Source | -67,000Source | -395,000Source |
| Stockholders' Equity Attributable to ParentUSD | 48,790,000Source | 49,392,000Source | 26,532,000Source | 58,606,000Source | 52,388,000Source | 34,709,000Source | 70,876,000Source | 60,894,000Source | 45,388,000Source | 82,949,000Source | 69,739,000Source | 106,343,000Source |
| Liabilities and EquityUSD | 63,780,000Source | 62,896,000Source | 37,329,000Source | 75,739,000Source | 66,051,000Source | 49,172,000Source | 84,807,000Source | 74,038,000Source | 61,884,000Source | 97,190,000Source | 81,637,000Source | 116,191,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 14,706,000Source | 12,525,000Source | 10,797,000Source | 16,669,000Source | 12,522,000Source | 14,463,000Source | 13,291,000Source | 11,843,000Source | 16,394,000Source | 13,428,000Source | 10,440,000Source | 7,808,000Source |
| Operating Lease, Liability, CurrentUSD | 726,000Source | 707,000Source | 457,000Source | 721,000Source | 702,000Source | 646,000Source | 716,000Source | 696,000Source | 730,000Source | 710,000Source | 691,000Source | 675,000Source |
| Accounts Payable, CurrentUSD | 2,441,000Source | 4,643,000Source | 3,986,000Source | 6,010,000Source | 5,108,000Source | 5,480,000Source | 3,629,000Source | 5,191,000Source | 8,087,000Source | 4,821,000Source | 1,966,000Source | 1,956,000Source |
| Operating Lease, Liability, NoncurrentUSD | 284,000Source | 979,000Source | 0Source | 464,000Source | 1,141,000Source | 0Source | 640,000Source | 1,301,000Source | 102,000Source | 813,000Source | 1,458,000Source | 2,040,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 11,539,000Source | 7,175,000Source | 6,354,000Source | 9,938,000Source | 6,712,000Source | 8,337,000Source | 8,946,000Source | 5,956,000Source | 7,577,000Source | 7,897,000Source | 7,783,000Source | 5,177,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 60,600,000Source | 57,700,000Source | 34,500,000Source | 71,000,000Source | 60,300,000Source | 46,100,000Source | 79,900,000Source | 67,200,000Source | 58,300,000Source | 91,700,000Source | 74,800,000Source | 105,300,000Source |
| Short-term InvestmentsUSD | 50,456,000Source | 44,629,000Source | 25,323,000Source | 60,173,000Source | 34,818,000Source | 37,512,000Source | 55,792,000Source | 48,529,000Source | 40,834,000Source | 40,276,000Source | 53,168,000Source | 88,920,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 87,000Source | 93,000Source | 364,000Source | 404,000Source | 398,000Source | 236,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,660,000Source | 1,365,000Source | 5,693,000Source | 4,760,000Source | 4,509,000Source | 4,256,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 9,000Source | -368,000Source | -591,000Source | 484,000Source | -483,000Source | 236,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -8,828,000Source | -9,263,000Source | -9,089,000Source | 23,956,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,288,000Source | -12,794,000Source | -37,923,000Source | -37,693,000Source | -30,887,000Source | -33,820,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 3,257,000Source | -14,584,000Source | 1,342,000Source | 13,728,000Source | 36,195,000Source | 38,149,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 44,000Source | 80,000Source | 582,000Source | 1,006,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 105,000Source | 3,000Source | 2,581,000Source | 53,780,000Source | 0Source | 75,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -8,926,000Source | -27,375,000Source | -34,000,000Source | 29,815,000Source | 5,308,000Source | 4,404,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 10,135,000Source | 13,038,000Source | 9,197,000Source | 10,784,000Source | 8,544,000Source | 24,095,000Source | 17,470,000Source | 51,470,000Source | 21,655,000Source | 16,347,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,384,000Source | 1,253,000Source | 920,000Source | 1,683,000Source | 1,660,000Source | 1,365,000Source | 5,693,000Source | 4,760,000Source | 4,509,000Source | 4,256,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 60,600,000Source | 57,700,000Source | 34,500,000Source | 71,000,000Source | 46,100,000Source | 79,900,000Source | 58,300,000Source | 91,700,000Source | 74,800,000Source | 105,300,000Source |
| DepreciationUSD | — | — | 89,000Source | 101,000Source | 87,000Source | 94,000Source | 87,000Source | 93,000Source | 400,000Source | 400,000Source | 400,000Source | 200,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 716,000Source | 741,000Source | 382,000Source | 835,000Source | 506,000Source | 941,000Source | 3,104,000Source | 3,259,000Source | 4,069,000Source | 1,581,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,258,000Source | -11,855,000Source | -9,232,000Source | -13,943,000Source | -12,345,000Source | -13,434,000Source | -45,851,000Source | -45,431,000Source | -41,441,000Source | -38,704,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,264,000Source | -11,861,000Source | -9,238,000Source | -13,949,000Source | -12,351,000Source | -13,440,000Source | -45,876,000Source | -45,455,000Source | -41,465,000Source | -38,728,000Source |
| Nonoperating Income (Expense)USD | — | — | 716,000Source | 746,000Source | 383,000Source | 834,000Source | 505,000Source | 948,000Source | 3,109,000Source | 3,220,000Source | 3,971,000Source | 1,198,000Source |
| Operating ExpensesUSD | — | — | 12,094,000Source | 12,766,000Source | 9,719,000Source | 14,898,000Source | 12,891,000Source | 14,491,000Source | 49,553,000Source | 49,334,000Source | 45,900,000Source | 40,288,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 5,000Source | 1,000Source | -1,000Source | -1,000Source | 7,000Source | 5,000Source | -39,000Source | — | — |
| Payments for Repurchase of WarrantsUSD | — | — | — | — | — | — | — | — | 169,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 53,407,000Source | — | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 15,826,000Source | 21,228,000Source | 71,111,000Source | 27,106,000Source | 86,552,000Source | 76,445,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 105,000Source | 3,000Source | 493,000Source | 373,000Source | 0Source | 75,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 120,000Source | 165,000Source | 104,000Source | 121,000Source | 41,000Source | 109,000Source | 593,000Source | 683,000Source | 488,000Source | 386,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 3,897,000Source | 3,126,000Source | 3,804,000Source | 3,318,000Source | 6,126,000Source | 4,014,000Source | 14,224,000Source | 12,482,000Source | 13,043,000Source | 13,181,000Source |
| Operating Income (Loss)USD | — | — | -11,974,000Source | -12,601,000Source | -9,615,000Source | -14,777,000Source | -12,850,000Source | -14,382,000Source | -48,960,000Source | -48,651,000Source | -45,412,000Source | -39,902,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 5,000Source | 1,000Source | -1,000Source | -1,000Source | 7,000Source | 5,000Source | -39,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -45,851,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,258,000Source | -11,855,000Source | -9,232,000Source | -13,943,000Source | -12,345,000Source | -13,434,000Source | -45,851,000Source | -45,431,000Source | -41,441,000Source | -38,704,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.17Source | -0.25Source | -0.14Source | -0.21Source | -0.18Source | -0.2Source | -0.69Source | -0.95Source | -0.93Source | -0.89Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.17Source | -0.25Source | -0.14Source | -0.21Source | -0.18Source | -0.2Source | -0.69Source | -0.95Source | -0.93Source | -0.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 66,879,000Source | 46,865,000Source | 68,397,000Source | 66,526,000Source | 68,350,000Source | 66,524,000Source | 66,841,000Source | 47,650,000Source | 44,677,000Source | 43,600,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 66,879,000Source | 46,865,000Source | 68,397,000Source | 66,526,000Source | 68,350,000Source | 66,524,000Source | 66,841,000Source | 47,650,000Source | 44,677,000Source | 43,600,000Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -45,851,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 716,000Source | 741,000Source | 382,000Source | 835,000Source | 506,000Source | 941,000Source | 3,104,000Source | 3,259,000Source | 4,069,000Source | 1,581,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,264,000Source | -11,861,000Source | -9,238,000Source | -13,949,000Source | -12,351,000Source | -13,440,000Source | -45,876,000Source | -45,455,000Source | -41,465,000Source | -38,728,000Source |
| Nonoperating Income (Expense)USD | — | — | 716,000Source | 746,000Source | 383,000Source | 834,000Source | 505,000Source | 948,000Source | 3,109,000Source | 3,220,000Source | 3,971,000Source | 1,198,000Source |
| Operating ExpensesUSD | — | — | 12,094,000Source | 12,766,000Source | 9,719,000Source | 14,898,000Source | 12,891,000Source | 14,491,000Source | 49,553,000Source | 49,334,000Source | 45,900,000Source | 40,288,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 25,000Source | 24,000Source | 24,000Source | 24,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 27,100,000Source |
Filing attachments
crdf-ex99_1.htm · 8-K · 2026-11-12
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have now exceeded 21 months on treatment Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027 SAN DIEGO, Calif., No…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-27
Exhibit 99.1 Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies SAN DIEGO, Calif., October 27, 2026 - Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alla…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-14
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, September 14, 2026 - Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Nerviano Medical Sciences S.r.l. (“NMS”) today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes betwee…
Read attachment ↗crdf-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 crdf-ex99_1.htm EX-99.1 EX-99.1 Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following successful End-of-Phase 2 meeting with FDA, Company aligned on key elements of registrational trial; plans to initiate study in Q1 2027, subject to securing …
Read attachment ↗crdf-ex99_1.htm · S-8 · 2026-07-21
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Josh Muntner (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in the number and subject to terms and conditions of this Stock Option Grant Agreement (the “Gran…
Read attachment ↗crdf-ex99_2.htm · S-8 · 2026-07-21
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Ajay Aggarwal (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in the number and subject to terms and conditions of this Stock Option Grant Agreement (the “Gra…
Read attachment ↗